Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01998724
Other study ID # 2012P000220
Secondary ID R01AT006358
Status Completed
Phase N/A
First received
Last updated
Start date August 2012
Est. completion date September 2018

Study information

Verified date October 2018
Source Beth Israel Deaconess Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this study is to determine the feasibility and effects of a 6-month tai chi exercise program as compared to a 6-month group walking program and standard care for patients with COPD that have recently completed a pulmonary rehabilitation program.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date September 2018
Est. primary completion date January 2018
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria:

1. COPD defined as FEV1 (Forced expiratory volume in 1 second)/FVC (Forced vital capacity) <0.70 or chest CT evidence of emphysema

2. Age > 40 years

3. Any severity of COPD as defined by GOLD (Global Obstructive Lung Disease) stages 1, 2,3, or 4

4. Completion of standard pulmonary rehabilitation of at least 8 weeks duration within 24 weeks prior to study entry* *Defined as attending 65% of the program's sessions with a minimum of 10 sessions

Exclusion Criteria:

1. COPD exacerbation requiring steroids, antibiotics, ED visit or hospitalization within the past 2 weeks unless physician deems subject at baseline

2. Hypoxemia on walk test (O2 sat < 85% on oxygen)

3. Inability to ambulate due to vascular or other neuromuscular conditions that would preclude a walk test

4. Clinical signs of unstable cardiovascular disease (ie. chest pain on walk test)

5. Severe cognitive dysfunction (documented Mini-Mental Status Exam = 24)

6. Non-English speaking

7. Current regular practice of tai chi

8. Current diagnosis of lung cancer or treated for lung cancer within the past 5 years

9. Unstable/untreated mental health issue that precludes informed consent or otherwise affects ability to participate in the intervention

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Tai Chi
24 week tai chi intervention designed for individuals with COPD
Group Walking
24 week group walking intervention

Locations

Country Name City State
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States VA Healthcare System Boston Massachusetts

Sponsors (3)

Lead Sponsor Collaborator
Beth Israel Deaconess Medical Center National Center for Complementary and Integrative Health (NCCIH), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of tai chi intervention Willingness to participate, adherence, and safety 24 weeks
Secondary Change from baseline - Disease specific quality of life Chronic Respiratory Questionnaire Baseline, 12 weeks, 24 weeks, 1 year
Secondary Change from baseline - Exercise capacity Six minute walk distance Baseline, 12 weeks, 24 weeks
Secondary Change from baseline - Dyspnea University of California, San Diego Shortness of Breath Questionnaire Baseline, 12 weeks, 24 weeks, 1 year
Secondary Change from baseline - Psychosocial well-being Center for Epidemiologic Studies Depression Scale, Perceived Stress Scale, COPD Self-Efficacy Scale, Multidimensional Scale of Perceived Social Support Baseline, 12 weeks, 24 weeks, 1 year
Secondary Changes from baseline - Pulmonary function Spirometry Baseline, 12 weeks, 24 weeks
Secondary Change from baseline - Exercise Efficacy Daily exercise activities, step counts taken at baseline, 12 weeks, 24 weeks, 1 year Throughout study
See also
  Status Clinical Trial Phase
Completed NCT03282019 - Study of Long-term HFNC for COPD Patients With HOT N/A
Completed NCT05573464 - A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease Phase 3
Recruiting NCT06040086 - Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations Phase 3
Not yet recruiting NCT06376994 - Multi-Center Clean Air Randomized Controlled Trial in COPD Phase 3
Completed NCT02728674 - Management of Patients With Respiratory Symptoms in Sweden N/A
Completed NCT02797392 - Feasibility of a Preventive Program Against Lifestyle Related Diseases N/A
Completed NCT02926534 - Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan N/A
Recruiting NCT02415478 - Bronchioscopic Lung Volume Reduction (BLVR) N/A
Completed NCT02512510 - Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT02459080 - Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT02518139 - A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT03487406 - Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2) Phase 2
Completed NCT02774226 - Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT01908140 - Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT01908933 - Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema Phase 3
Completed NCT01893476 - A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management N/A
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT01701869 - Microbiology & Immunology of the Chronically-inflamed Airway N/A
Recruiting NCT02527486 - Seoul National University Airway Registry N/A
Withdrawn NCT01377428 - Efficacy of Indacaterol 150 µg Versus Formoterol Phase 4